Table 2.
Changes in the BCVA and CRT from baseline after IVR treatment in tAMD and PCV patients.
| 1 month | P value | 3 months | P value | |||
|---|---|---|---|---|---|---|
| Mean | Median (Interquartile range) |
Mean | Median (Interquartile range) |
|||
|
| ||||||
| BCVA | ||||||
| PCV | −0.0086 | 0.00 (−0.090–0.00) | .38* | −0.011 | 0.00 (−0.12–0.030) | .55* |
| tAMD | −0.093 | 0.00 (−0.17–0.00) | .0084* | −0.19 | −0.12 (−0.30–0.00) | .00080* |
| P value | .42† | .0045† | ||||
|
| ||||||
| CRT | ||||||
| PCV | −118 | −111 (−166–−32) | <.0001* | −173 | −130 (−212–−63) | <.0001* |
| tAMD | −104 | −84 (−147–−57) | <.0001* | −129 | −97 (−182–−64) | <.0001* |
| P value | .80† | .58† | ||||
BCVA: best-corrected visual acuity (LogMAR); CRT: central retinal thickness.
*Wilcoxon's signed-rank test (comparison to baseline).
†Mann-Whitney U test (comparison between PCV and tAMD at the same month).